Irish pharma company Open Orphan eyeing profit on back of Covid research work

Specialist Irish pharmaceutical services group Open Orphan is targeting operating profitability by the third quarter of this year, on the back of growing involvement in Covid-19 testing and research work.

The company reported an operating loss of €14.2m for 2019 and reduced revenues of €27m. Both figures include its two main acquisitions of Irish firm Venn Life Sciences and UK pharmaceutical services business hVIVO.